336 related articles for article (PubMed ID: 31663374)
21. Effects of Gadolinium Depositions in Vivo.
Bruno D; Vealé BL
Radiol Technol; 2021 Sep; 93(1):46-54. PubMed ID: 34588278
[TBL] [Abstract][Full Text] [Related]
22. Gadolinium tissue deposition in brain and bone.
Murata N; Murata K; Gonzalez-Cuyar LF; Maravilla KR
Magn Reson Imaging; 2016 Dec; 34(10):1359-1365. PubMed ID: 27720805
[TBL] [Abstract][Full Text] [Related]
23. Oral Manganese Chloride Tetrahydrate: A Novel Magnetic Resonance Liver Imaging Agent for Patients With Renal Impairment: Efficacy, Safety, and Clinical Implication.
Brismar TB; Geisel D; Kartalis N; Madrazo BL; Persson Hedman H; Norlin A
Invest Radiol; 2024 Feb; 59(2):197-205. PubMed ID: 37934630
[TBL] [Abstract][Full Text] [Related]
24. Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommendation for Suspension of the Marketing Authorizations for 4 Linear Agents.
Runge VM
Invest Radiol; 2017 Jun; 52(6):317-323. PubMed ID: 28368880
[TBL] [Abstract][Full Text] [Related]
25. High Levels of Gadolinium Deposition in the Skin of a Patient With Normal Renal Function.
Roberts DR; Lindhorst SM; Welsh CT; Maravilla KR; Herring MN; Braun KA; Thiers BH; Davis WC
Invest Radiol; 2016 May; 51(5):280-9. PubMed ID: 26953564
[TBL] [Abstract][Full Text] [Related]
26. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
27. The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review.
Olchowy C; Cebulski K; Łasecki M; Chaber R; Olchowy A; Kałwak K; Zaleska-Dorobisz U
PLoS One; 2017; 12(2):e0171704. PubMed ID: 28187173
[TBL] [Abstract][Full Text] [Related]
28. Gadolinium-Based Contrast Agent Use, Their Safety, and Practice Evolution.
Do C; DeAguero J; Brearley A; Trejo X; Howard T; Escobar GP; Wagner B
Kidney360; 2020 Jun; 1(6):561-568. PubMed ID: 34423308
[TBL] [Abstract][Full Text] [Related]
29. Acute Chelation Therapy-Associated Changes in Urine Gadolinium, Self-reported Flare Severity, and Serum Cytokines in Gadolinium Deposition Disease.
Maecker HT; Siebert JC; Rosenberg-Hasson Y; Koran LM; Ramalho M; Semelka RC
Invest Radiol; 2021 Jun; 56(6):374-384. PubMed ID: 33449576
[TBL] [Abstract][Full Text] [Related]
30. Gadolinium-based contrast agents: why nephrologists need to be concerned.
Leyba K; Wagner B
Curr Opin Nephrol Hypertens; 2019 Mar; 28(2):154-162. PubMed ID: 30531473
[TBL] [Abstract][Full Text] [Related]
31. Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents.
Thomsen HS; Marckmann P; Logager VB
Cancer Imaging; 2007 Sep; 7(1):130-7. PubMed ID: 17905680
[TBL] [Abstract][Full Text] [Related]
32. Gadolinium Deposition and Chronic Toxicity.
Ramalho J; Ramalho M
Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):765-778. PubMed ID: 28964466
[TBL] [Abstract][Full Text] [Related]
33. Gadolinium Deposition Disease: Current State of Knowledge and Expert Opinion.
Semelka RC; Ramalho M
Invest Radiol; 2023 Aug; 58(8):523-529. PubMed ID: 37058336
[TBL] [Abstract][Full Text] [Related]
34. Gadolinium Deposition: A Study Review.
Strickler SE; Clark KR
Radiol Technol; 2021 Jan; 92(3):249-258. PubMed ID: 33472877
[TBL] [Abstract][Full Text] [Related]
35. Contemporary applications and limitations of magnetic resonance imaging contrast materials.
Natalin RA; Prince MR; Grossman ME; Silvers D; Landman J
J Urol; 2010 Jan; 183(1):27-33. PubMed ID: 19913804
[TBL] [Abstract][Full Text] [Related]
36. Gadolinium Deposition in Human Brain Tissues after Contrast-enhanced MR Imaging in Adult Patients without Intracranial Abnormalities.
McDonald RJ; McDonald JS; Kallmes DF; Jentoft ME; Paolini MA; Murray DL; Williamson EE; Eckel LJ
Radiology; 2017 Nov; 285(2):546-554. PubMed ID: 28653860
[TBL] [Abstract][Full Text] [Related]
37. Gadolinium contrast agents - are they really safe?
Malikova H; Holesta M
J Vasc Access; 2017 Mar; 18(Suppl. 2):1-7. PubMed ID: 28362042
[TBL] [Abstract][Full Text] [Related]
38. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.
Schieda N; Blaichman JI; Costa AF; Glikstein R; Hurrell C; James M; Jabehdar Maralani P; Shabana W; Tang A; Tsampalieros A; van der Pol CB; Hiremath S
Can J Kidney Health Dis; 2018; 5():2054358118778573. PubMed ID: 29977584
[TBL] [Abstract][Full Text] [Related]
39. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting.
Broome DR
Eur J Radiol; 2008 May; 66(2):230-4. PubMed ID: 18372138
[TBL] [Abstract][Full Text] [Related]
40. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
Canavese C; Mereu MC; Aime S; Lazzarich E; Fenoglio R; Quaglia M; Stratta P
J Nephrol; 2008; 21(3):324-36. PubMed ID: 18587720
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
